In clinical exome and genome sequencing, there is a potential for the recognition and
reporting of incidental or secondary findings unrelated to the indication for ordering the …

Disclaimer: These recommendations are designed primarily as an educational resource for
medical geneticists and other healthcare providers to help them provide quality medical …

Objective. —Neurofibromatosis 1 and neurofibromatosis 2 are autosomal dominant genetic
disorders in which affected individuals develop both benign and malignant tumors at an …

Background Tuberous sclerosis complex is highly variable in clinical presentation and
findings. Disease manifestations continue to develop over the lifetime of an affected individual. …

Purpose By incorporating major developments in genetics, ophthalmology, dermatology,
and neuroimaging, to revise the diagnostic criteria for neurofibromatosis type 1 (NF1) and to …

Background Tuberous sclerosis complex is a genetic disorder affecting every organ system,
but disease manifestations vary significantly among affected individuals. The diverse and …

Neurofibromatosis type 1 is a complex autosomal dominant disorder caused by germline
mutations in the NF1 tumour suppressor gene. Nearly all individuals with neurofibromatosis …

Neurofibromatosis type 1 (NF1) is an autosomal dominant condition with a worldwide incidence
of ∼1 per 2500 to 3000 individuals. Caused by a germ-line–inactivating mutation in the …

Germline mutations in the tumour suppressor gene PTEN have been implicated in two
hamartoma syndromes that exhibit some clinical overlap, Cowden syndrome (CS) and Bannayan-…

Neurofibromatosis type 1 (NF1) is an autosomal dominant, multisystem disorder affecting
approximately 1 in 3500 people. Significant advances in the understanding of the …